In pancreatic ductal adenocarcinoma patients, early results of RMC-6236 suggested an ORR of 20% with a DCR of 87%, with also a marked reduction in the measurement of mutant KRAS alleles in circulating tumor DNA studies. The gene discussed is KRAS; the disease is pancreatic ductal adenocarcinoma.